142 related articles for article (PubMed ID: 11365714)
1. Hydroxyurea - new observations.
Proj Inf Perspect; 1998 Apr; (24):15-7. PubMed ID: 11365714
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea for HIV infection.
Zachary KC; Davis B
AIDS Clin Care; 1998 Apr; 10(4):25-6, 32. PubMed ID: 11365149
[TBL] [Abstract][Full Text] [Related]
3. Is Hydroxyurea for real?
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
[TBL] [Abstract][Full Text] [Related]
4. Hydroxyurea in HIV therapy.
HIV Hotline; 1998 Mar; 8(1):5-7. PubMed ID: 11365359
[TBL] [Abstract][Full Text] [Related]
5. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir).
Lori F; Jessen H; Lieberman J; Clerici M; Tinelli C; Lisziewicz J
AIDS Res Hum Retroviruses; 1999 May; 15(7):619-24. PubMed ID: 10331440
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
[TBL] [Abstract][Full Text] [Related]
7. Absence of viral rebound after treatment of HIV-infected patients with didanosine and hydroxycarbamide.
Vila J; Nugier F; Barguès G; Vallet T; Peyramond D; Hamedi-Sangsari F; Seigneurin JM
Lancet; 1997 Aug; 350(9078):635-6. PubMed ID: 9288048
[No Abstract] [Full Text] [Related]
8. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
[TBL] [Abstract][Full Text] [Related]
9. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
[TBL] [Abstract][Full Text] [Related]
10. Dethroning AZT.
Gilden D; Falkenberg J; Torres G
GMHC Treat Issues; 1997 Feb; 11(2):10-3. PubMed ID: 11364106
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.
Barreiro P; de Mendoza C; Camino N; García-Benayas T; Blanco F; Núñez M; González-Lahoz J; Soriano V
HIV Clin Trials; 2003; 4(6):361-71. PubMed ID: 14628279
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyurea: overview of clinical data and antiretroviral and immunomodulatory effects.
Lori F; Lisziewicz J
Antivir Ther; 1999; 4 Suppl 3():101-8. PubMed ID: 16021881
[TBL] [Abstract][Full Text] [Related]
13. [Hydroxyurea and HIV infection].
Nkoghe D; Kola L; Léonard P; Demonty J; Moutschen M
Rev Med Liege; 2000 Jul; 55(7):721-4. PubMed ID: 11014107
[TBL] [Abstract][Full Text] [Related]
14. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
[TBL] [Abstract][Full Text] [Related]
15. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Havlir DV; Gilbert PB; Bennett K; Collier AC; Hirsch MS; Tebas P; Adams EM; Wheat LJ; Goodwin D; Schnittman S; Holohan MK; Richman DD;
AIDS; 2001 Jul; 15(11):1379-88. PubMed ID: 11504959
[TBL] [Abstract][Full Text] [Related]
16. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
17. Double protease inhibitor combinations.
Proj Inf Perspect; 1998 Apr; (24):6-8. PubMed ID: 11365719
[TBL] [Abstract][Full Text] [Related]
18. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
[TBL] [Abstract][Full Text] [Related]
19. Immune reconstitution: conference reports.
Whitfield L
Posit Aware; 1998; 9(5):36-9, 41-3. PubMed ID: 11365894
[TBL] [Abstract][Full Text] [Related]
20. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
